<p>Personalis (纳斯达克：PSNL - 获取免费报告) 的目标股价在周五发布的一份报告中被 Needham &amp; Company LLC 的分析师从$5.50 上调至$7.25，据 Benzinga 报道。该公司目前对该股票给予&#34;买入&#34;评级。Needham &amp; Company LLC 的目标股价预计将使股价潜在上涨 24.36%。</p>
<p>另外，Lake Street Capital 在 4 月 30 日星期二的研究报告中开始对 Personalis 进行覆盖。他们为该公司发行了&#34;买入&#34;评级，并设定了$4.00 的目标股价。</p>
<p><strong>查看我们对 PSNL 的最新分析</strong></p>
<h2>Personalis 股票表现</h2>
<p>纳斯达克：PSNL 的股价在周五上涨了$0.76，达到$5.83。该股交易量为 4,918,409 股，相比平均交易量 655,506 股有所增加。Personalis 的 12 个月最低价为$0.89，最高价为$7.20。该公司的 50 天移动平均股价为$2.26，200 天移动平均股价为$1.71。该公司的市值为 3.0946 亿美元，市盈率为-3.14，贝塔系数为 1.85。</p>
<p>Personalis (纳斯达克：PSNL - 获取免费报告) 上次公布其财报是在 8 月 7 日星期三。该公司本季度每股亏损 ($0.24)，超过了每股亏损 ($0.34) 的共识预期$0.10。Personalis 的净利润率为-101.78%，净资产回报率为-56.87%。该公司本季度收入为 2,258 万美元，超过了共识预期的 1,981 万美元。去年同期，该公司每股亏损 ($0.50)。作为一组，卖方分析师预计 Personalis 今年将发布-1.17 美元的每股收益。</p>
<h2>机构资金流入和流出</h2>
<p>大型投资者最近增加或减少了他们在该股票中的持股。Acadian Asset Management LLC 在第二季度将其在 Personalis 的持股增加了 6.7%。Acadian Asset Management LLC 现在拥有该公司的 1,057,956 股股票，价值$1,237,000，较之前增持了 66,128 股。ARK Investment Management LLC 在第二季度增加了其在 Personalis 的持仓 4.9%。ARK Investment Management LLC 现在拥有该公司的 6,361,886 股股票，价值$7,443,000，较之前增持了 296,413 股。Virtu Financial LLC 在第一季度购入了一笔新的 Personalis 股票，价值约为$41,000。Jacobs Levy Equity Management Inc.在第一季度将其在 Personalis 的持股增加了 144.7%。Jacobs Levy Equity Management Inc.现在拥有该公司的 821,657 股股票，价值$1,224,000，较上一季度增持了 485,822 股。最后，俄亥俄州公务员退休系统在第一季度购入了一笔新的 Personalis 股票，价值约为$29,000。对冲基金和其他机构投资者拥有该公司股票的 61.91%。</p>
<h2>关于 Personalis（获取免费报告）</h2>
<p>Personalis, Inc.主要在美国、欧洲和亚太地区开发和推广先进的癌症基因组检测和分析。其检测和分析被制药公司用于转化研究、生物标志物发现和个性化癌症治疗的开发，医生使用先进检测来检测癌症复发、监测癌症演变，并为治疗选择提供见解。</p>
<h2>精选文章</h2>
<ul>
<li>我们喜欢的五只股票</li>
<li>什么是盈利惊喜？</li>
<li>京东的盈利惊喜：中国的前景好于预期</li>
<li>内部买入解释：投资者需要了解的内容</li>
<li>沃伦·巴菲特最近的股票交易：值得关注的买入和卖出</li>
<li>一些最佳大市值股票是什么？</li>
<li>Sea Limited 的电子商务和金融科技实力推动股价飙升</li>
</ul>
<p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 您尚未拥有的第一加密货币（来自 Crypto 101 Media）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc2"/></p>
<h2>您现在是否应该投资$1,000 在 Personalis？</h2>
<p>在考虑 Personalis 之前，您会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Personalis 不在名单上。</p>
<p>尽管 Personalis 目前在分析师中有&#34;买入&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

PSNL

<p>Needham & Company LLC 将 Personalis（纳斯达克股票代码：PSNL）的目标股价从 0.50 美元上调至 0.25 美元，并维持对该股票的 “买入” 评级。这表明潜在上涨空间为 24.36%。该公司最近的交易表现显示股价上涨至 0.83 美元，并报告的每股收益好于预期。机构投资者也增加了对 Personalis 的持股</p>

<p>Personalis (NASDAQ:PSNL - Get Free Report) had its price objective raised by analysts at Needham &amp; Company LLC from $5.50 to $7.25 in a note issued to investors on Friday, Benzinga reports. The firm currently has a &#34;buy&#34; rating on the stock. Needham &amp; Company LLC's price objective would suggest a potential upside of 24.36% from the stock's current price.</p>
<div class="lb-trans"><p>Personalis (纳斯达克：PSNL - 获取免费报告) 的目标股价在周五发布的一份报告中被 Needham &amp; Company LLC 的分析师从$5.50 上调至$7.25，据 Benzinga 报道。该公司目前对该股票给予&#34;买入&#34;评级。Needham &amp; Company LLC 的目标股价预计将使股价潜在上涨 24.36%。</p>
</div><p>Separately, Lake Street Capital assumed coverage on Personalis in a research note on Tuesday, April 30th. They issued a &#34;buy&#34; rating and a $4.00 price objective for the company.</p>
<div class="lb-trans"><p>另外，Lake Street Capital 在 4 月 30 日星期二的研究报告中开始对 Personalis 进行覆盖。他们为该公司发行了&#34;买入&#34;评级，并设定了$4.00 的目标股价。</p>
</div><p><strong>View Our Latest Analysis on PSNL</strong></p>
<div class="lb-trans"><p><strong>查看我们对 PSNL 的最新分析</strong></p>
</div><h2>Personalis Stock Performance</h2>
<div class="lb-trans"><h2>Personalis 股票表现</h2>
</div><p>Shares of NASDAQ:PSNL traded up $0.76 on Friday, hitting $5.83. The stock had a trading volume of 4,918,409 shares, compared to its average volume of 655,506. Personalis has a twelve month low of $0.89 and a twelve month high of $7.20. The firm's 50 day moving average price is $2.26 and its 200-day moving average price is $1.71. The company has a market capitalization of $309.46 million, a price-to-earnings ratio of -3.14 and a beta of 1.85.</p>
<div class="lb-trans"><p>纳斯达克：PSNL 的股价在周五上涨了$0.76，达到$5.83。该股交易量为 4,918,409 股，相比平均交易量 655,506 股有所增加。Personalis 的 12 个月最低价为$0.89，最高价为$7.20。该公司的 50 天移动平均股价为$2.26，200 天移动平均股价为$1.71。该公司的市值为 3.0946 亿美元，市盈率为-3.14，贝塔系数为 1.85。</p>
</div><p>Personalis (NASDAQ:PSNL - Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.10. Personalis had a negative net margin of 101.78% and a negative return on equity of 56.87%. The firm had revenue of $22.58 million for the quarter, compared to the consensus estimate of $19.81 million. During the same period last year, the company posted ($0.50) EPS. As a group, sell-side analysts predict that Personalis will post -1.17 EPS for the current year.</p>
<div class="lb-trans"><p>Personalis (纳斯达克：PSNL - 获取免费报告) 上次公布其财报是在 8 月 7 日星期三。该公司本季度每股亏损 ($0.24)，超过了每股亏损 ($0.34) 的共识预期$0.10。Personalis 的净利润率为-101.78%，净资产回报率为-56.87%。该公司本季度收入为 2,258 万美元，超过了共识预期的 1,981 万美元。去年同期，该公司每股亏损 ($0.50)。作为一组，卖方分析师预计 Personalis 今年将发布-1.17 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Large investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC grew its holdings in shares of Personalis by 6.7% in the second quarter. Acadian Asset Management LLC now owns 1,057,956 shares of the company's stock worth $1,237,000 after acquiring an additional 66,128 shares during the period. ARK Investment Management LLC raised its position in Personalis by 4.9% during the second quarter. ARK Investment Management LLC now owns 6,361,886 shares of the company's stock valued at $7,443,000 after purchasing an additional 296,413 shares during the period. Virtu Financial LLC bought a new position in shares of Personalis during the first quarter valued at approximately $41,000. Jacobs Levy Equity Management Inc. grew its stake in shares of Personalis by 144.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 821,657 shares of the company's stock valued at $1,224,000 after buying an additional 485,822 shares during the last quarter. Finally, Public Employees Retirement System of Ohio bought a new position in Personalis in the first quarter worth approximately $29,000. Hedge funds and other institutional investors own 61.91% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了他们在该股票中的持股。Acadian Asset Management LLC 在第二季度将其在 Personalis 的持股增加了 6.7%。Acadian Asset Management LLC 现在拥有该公司的 1,057,956 股股票，价值$1,237,000，较之前增持了 66,128 股。ARK Investment Management LLC 在第二季度增加了其在 Personalis 的持仓 4.9%。ARK Investment Management LLC 现在拥有该公司的 6,361,886 股股票，价值$7,443,000，较之前增持了 296,413 股。Virtu Financial LLC 在第一季度购入了一笔新的 Personalis 股票，价值约为$41,000。Jacobs Levy Equity Management Inc.在第一季度将其在 Personalis 的持股增加了 144.7%。Jacobs Levy Equity Management Inc.现在拥有该公司的 821,657 股股票，价值$1,224,000，较上一季度增持了 485,822 股。最后，俄亥俄州公务员退休系统在第一季度购入了一笔新的 Personalis 股票，价值约为$29,000。对冲基金和其他机构投资者拥有该公司股票的 61.91%。</p>
</div><h2>About Personalis (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 Personalis（获取免费报告）</h2>
</div><p>Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.</p>
<div class="lb-trans"><p>Personalis, Inc.主要在美国、欧洲和亚太地区开发和推广先进的癌症基因组检测和分析。其检测和分析被制药公司用于转化研究、生物标志物发现和个性化癌症治疗的开发，医生使用先进检测来检测癌症复发、监测癌症演变，并为治疗选择提供见解。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Personalis</li>
<li>What is an Earnings Surprise?</li>
<li>JD.com Earnings Surprise: China’s Outlook Better Than Expected</li>
<li>Insider Buying Explained: What Investors Need to Know</li>
<li>Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch</li>
<li>What Are Some of the Best Large-Cap Stocks to Buy?</li>
<li>Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge</li>
</ul>
<div class="lb-trans"><h2>精选文章</h2>
<ul>
<li>我们喜欢的五只股票</li>
<li>什么是盈利惊喜？</li>
<li>京东的盈利惊喜：中国的前景好于预期</li>
<li>内部买入解释：投资者需要了解的内容</li>
<li>沃伦·巴菲特最近的股票交易：值得关注的买入和卖出</li>
<li>一些最佳大市值股票是什么？</li>
<li>Sea Limited 的电子商务和金融科技实力推动股价飙升</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ The #1 Crypto That You Don’t Own… Yet (From Crypto 101 Media)(Ad)</p>
<div class="lb-trans"><p>→ 您尚未拥有的第一加密货币（来自 Crypto 101 Media）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9176&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Personalis right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资$1,000 在 Personalis？</h2>
</div><p>Before you consider Personalis, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Personalis 之前，您会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Personalis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Personalis 不在名单上。</p>
</div><p>While Personalis currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Personalis 目前在分析师中有&#34;买入&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Personalis（纳斯达克代码：PSNL）的目标价被 Needham & Company LLC 上调至 7.25 美元